Could a common diabetes drug shield hearts from AF-Related failure?

NCT ID NCT07482020

Recruiting now Disease control Sponsor: Huashan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether empagliflozin, a diabetes drug, can improve left atrial function in 66 people with paroxysmal atrial fibrillation, high blood pressure, and abnormal glucose metabolism. The goal is to see if it can prevent heart failure. Participants will be randomly assigned to receive the drug or a placebo, and heart function will be measured using advanced imaging.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: empagliflozin (an SGLT2 inhibitor)
What this could lead to: If it works, this could point toward a new way to prevent heart failure in people with atrial fibrillation and related metabolic problems.
What could go wrong: This is a small, early-phase trial (66 people) testing a surrogate marker, not hard outcomes. The drug may not improve heart function or prevent heart failure in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation diabetes mellitus hypertensive disorder paroxysmal atrial fibrillation prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION (AF) HYPERTENSION

Contacts and locations

Locations

Fudan University Affiliated Huashan Hospital, Cardiology Department
RECRUITING

Shanghai, Shanghai Municipality, 200036, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.